LUCID publishes new paper in Frontiers in Digital Health outlining scientific approach to using AI-personalized music in Alzheimer’s care. 

‍

TORONTO -- Today, LUCID Inc published a research paper in the journal Frontiers in Digital Health outlining their music-based digital therapeutic for people living with Alzheimer’s. LUCID proposed a digital therapeutic, dubbed LUC-101, which builds upon their therapeutic music AI which was previously clinically validated for adult anxiety. LUC-101 will be a software-based treatment which personalizes therapeutic music to reduce anxiety and agitation associated with Alzheimer’s and other dementias. 

‍

The paper outlines LUCID’s research with key opinion leaders in dementia care, development plans, and future exploratory trials to determine safety and efficacy. The authors, which include Dan Cohen of non-profit Music & Memory and Kate Dupuis of the Sheridan Centre of Elder Research, detail the rising adoption of music therapies within aging populations, and how personalized technology can help promote scalability.

‍

Neuropsychiatric symptoms such as anxiety and agitation present significant challenges and caregiver burdens. Music has been shown to provide significant benefits to people living with AD, due to music’s strong link to the memory system. Through surveys of geriatric and dementia care professionals and a comprehensive review of existing scientific literature, the paper identified a strong clinical case for a digital therapeutic using music to target neuropsychiatric symptoms.

‍

“The benefits of music for dementia have become increasingly recognized in recent years,” says Dr. Frank Russo, LUCID’s Chief Science Officer. “LUC-101 aims to target and optimize the therapeutic potential of music for those living with dementia, while bridging the gap of care.”

‍

LUCID previously published a clinical study on their AI system ‘AMRS’ (Affective Music Recommendation System) which found their technology effective in mitigating anxiety in otherwise healthy adults. Building on this proprietary AI system, ‘AMRS-D’ will target symptoms of anxiety and agitation within people living with dementia. 

‍

The digital therapeutic would enable caregivers to provide personalized therapeutic music to their loved one with dementia from home on a daily basis. The closed-loop feedback system will collect real-time psychometric and biometric data to drive the AI system, allowing the personalization to be driven by physiological data alone or with additional user input. The AI system will also adapt and become more optimized with each use.

‍

“Our goal is to create an effective and pleasing intervention that can be used on a regular basis, easing anxiety and agitation for those living with dementia, and increasing their overall quality of life,” says LUCID CEO Zach McMahon. 

‍

A preliminary clinical trial is planned for 2023 which will investigate the system’s safety and efficacy. LUCID has partnered with Sheridan Centre of Elder Research and Toronto Metropolitan University to conduct research and validation on this technology.

‍

About LUCID

‍

LUCID is transforming music into medicine. By unlocking the power of AI and neuroscience, they deliver personalized music-based therapies that are optimized for emotional outcomes. They aim to provide personalized, evidence-based, and accessible solutions in digital mental health care. Through scientific research and testing, LUCID is working towards the clinical validation of their technology.

LUCID’s latest clinical trial, The Effect of Music & Auditory Beat Stimulation on Anxiety, is published in PLOS One. For more information, please visit www.lucidtherapeutics.com.